BioForce Announces the Sale of the New Nano eNabler 5.0 to Europe
CHICAGO, IL (October 6, 2014) – BioForce Nanosciences, Inc. (BioForce) recently completed the installation of the newest version of its groundbreaking Nano eNabler Benchtop Molecular Printer. With increased optical resolution, state of the art computer hardware and Windows 8.1 operating system, the Nano eNabler will provide expanded capabilities for the research market. The Nano eNabler is the only system capable of femtoliter (10-18 to 10-15 liter) volume printing within the scientific research community. The ability to print a variety of molecules from protein and DNA to colloidal metals and nano-particles make the Nano eNabler a unique instrument.
“The sale and installation to the Università degli Studi di Palermo in Palermo, Italy is a significant step in the development of the Nano eNabler instrument,” noted Kerry Frey, BioForce President and CEO. “We anticipate completing multiple sales of our flagship instrument in the upcoming months,” added Mr. Frey.
Dr. Sebastiano Cataldo, a researcher at the Università degli Studi di Palermo, described the installation of the Nano eNabler as an “exciting and significant addition to the research capabilities of our lab.” Dr. Cataldo also noted, “We are extremely pleased with the installation and training conducted by the BioForce team and the creative opportunities the Nano eNabler will provide for our facility.”
Mr. Frey added, “In the near future, we will be offering opportunities for existing customers who currently utilize the older systems to upgrade their Nano eNablers to the new operating system. Providing state-of-the-art equipment to our customers continues to be a priority for BioForce.”
For further information about this release, please contact Judi Insley, Customer Relations Manager of BioForce at firstname.lastname@example.org or leave a voicemail at 515-233-8333. For additional information about BioForce, you are invited to explore our newly re-designed website at http://www.bioforcenano.com.
Comments are closed.